Akademisyen
ÖMÜR GÖKMEN SEVİNDİK
PROFESÖR
DEMİROĞLU BİLİM ÜNİVERSİTESİ TIP FAKÜLTESİ DAHİLİ TIP BİLİMLERİ BÖLÜMÜ
- Ana Dal Sağlık Bilimleri Temel Alanı
- Yan Dal Hematoloji (İç Hastalıkları)
Kayıtlı çıktılara kısa bakış — ayrıntılar aşağıda.
- Makale 80
- Proje 0
- Kitap 4
- Bildiri 226
- Patent 0
- Sanatsal 0
Scopus (SJR)
Q1
10
Q2
33
Q3
24
Q4
8
WoS (JCR)
Q1
10
Q2
11
Q3
24
Q4
28
TR Index
21
makale
Alan+yıl+tür normalize OpenAlex yüzdelik — Clarivate ESI / SciVal değildir.
Üst %1 makale
0
Üst %10 makale
3
Ort. yüzdelik
51.1%
Üst %1 payı
0.0%
Üst %10 payı
3.6%
Makaleler
YÖKSİS ve OpenAlex kaynak ayrımıyla makaleler; quartile ve TR Index ile daraltabilirsiniz.
Makale listesi
- 2025 Original vs. Generic Plerixafor for the Mobilization of Stem Cells in Multiple Myeloma Patients YÖKSİS SJR Q3 JCR Q4 OpenAlex 17.6%
- 2025 The Outcomes of Newly Diagnosed Multiple Myeloma Patients With Concurrent or Previous Solid Tumor History YÖKSİS SJR Q2 JCR Q1 OpenAlex 31.9%
- 2025 Real-Life Retrospective Turkiye Data of the De-Escalation of ABVD to AVD in Hodgkin Lymphoma: On Behalf of the TSH Turkish Lymphoma Study Group YÖKSİS SJR Q2 JCR Q1 OpenAlex 29.7%
- 2025 Real-World Outcomes of Antifungal Prophylaxis in Adult Acute Lymphoblastic Leukemia Patients: A Multicenter Comparison of the Use of Fluconazole and Micafungin YÖKSİS TR Index OpenAlex 27.3%
- 2025 Comprehensive analysis of FLT3-mutated patients with acute myeloid leukemia with updated 2022 European LeukemiaNet recommendations: insights from the Turkish AML registry project YÖKSİS SJR Q2 JCR Q2 OpenAlex 76.3%
- 2025 Clinical Characteristics, Treatment Approaches, and Survival Predictors in Adult Acute Myeloid Leukemia: Interim Results from the Turkish Society of Hematology AML Registry YÖKSİS SJR Q2 JCR Q1 OpenAlex 32.9%
- 2024 Successful use of split-dose intravenous daratumumab in a multiple myeloma patient after a first-dose life-threatening infusion-related reaction YÖKSİS SJR Q3 JCR Q4 OpenAlex 55.2%
- 2024 Obinutuzumab interference with immunoelectrophoresis in a case of follicular lymphoma YÖKSİS SJR Q2 JCR Q2 OpenAlex 7.1%
- 2024 Eltrombopag treatment in thrombocytopenia following hematopoietic stem cell transplantation: A multicenter real-world experience YÖKSİS SJR Q2 JCR Q3 OpenAlex 81.0%
- 2024 Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience YÖKSİS SJR Q2 JCR Q3 OpenAlex 75.8%
- 2023 Should Core Needle Lymph Node Biopsy be a Relevant Alternative to Surgical Excisional Biopsy in Diagnostic Work Up of Lymphomas? YÖKSİS TR Index SJR Q3 JCR Q3 OpenAlex 48.2%
- 2023 Germline genetic variants in Turkish familial multiple myeloma/monoclonal gammopathy of undetermined significance cases YÖKSİS SJR Q1 JCR Q1 OpenAlex 81.4%
- 2023 Inherited transmission of the CSF3R T618I mutation: a familial report YÖKSİS SJR Q1 JCR Q2 OpenAlex 12.6%
- 2023 Glofitamab in relapsed/refractory diffuse large B‐cell lymphoma: Real‐world data YÖKSİS SJR Q2 JCR Q2 OpenAlex üst %10 OpenAlex 94.9%
- 2023 Vitamin D Gene Polymophism in Patients with Aseptic Necrosis after Allogeneic Hematopoietic Stem Cell Transplantation YÖKSİS TR Index OpenAlex 9.6%
- 2023 The effect of haemoglobin, albumin, lymphocyte and platelet score on the prognosis in patients with multiple myeloma YÖKSİS SJR Q2 JCR Q3 OpenAlex 88.8%
- 2023 Plerixafor in autologous stem cell transplantation: Does it affect engraftment kinetics? YÖKSİS SJR Q3 JCR Q4 OpenAlex 61.4%
- 2022 Clinical Characteristics and Outcome of COVID-19 in Turkish Hematological Malignancy Patients YÖKSİS TR Index SJR Q3 JCR Q3 OpenAlex 75.2%
- 2022 Quality of Life Assessment with EORTC QLQ in Patients with Multiple Myeloma: Multicenter Study YÖKSİS TR Index OpenAlex 14.1%
- 2022 First-line Usage of Daratumumab, Lenalidomide, Dexamethasone (DRd) Combination in a Case of Castleman Disease Variant of Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome (CD-POEMS) YÖKSİS SJR Q1 JCR Q1 OpenAlex 72.8%